Kiniksa Pharmaceuticals International plc
Organization details
- Legal name
- Kiniksa Pharmaceuticals International plc
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- London
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KNSA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001730430
- EIN
- 98-1795578
Board of directors
-
Barry D. Quart · DirectorSince 2023
- Since 2023
-
G. Bradley Cole · DirectorSince 2023
- Since 2023
-
Kimberly J. Popovits · DirectorSince 2023
-
Meta Cantey Boyd · DirectorSince 2024
-
Richard S. Levy · DirectorSince 2023
-
Sanj K. Patel · Director · CHAIRMAN & CEOSince 2023
-
Thomas Malley · DirectorSince 2023
-
Tracey L. McCain · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 3, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
75.3%
-
82.1%
-
97.4%
-
97.6%
-
97.6%
-
97.6%
-
97.8%
-
97.8%
-
99.7%
Board connections
7 of this board's directors also sit on 23 other boards. 22 are in the same sector.
-
BeOne Medicines Ltd. Same sectorvia Felix Baker, Julian Baker and Thomas Malley
-
Kodiak Sciences Inc Same sectorvia Felix Baker, Julian Baker and Richard S. Levy
-
Madrigal Pharmaceuticals Inc. Same sectorvia Felix Baker, Julian Baker and Richard S. Levy
-
ACADIA Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
Bicycle Therapeutics plc Same sectorvia Felix Baker and Julian Baker
-
DBV Technologies S.A. Same sectorvia Felix Baker and Julian Baker
-
Denali Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Immunocore Holdings plc Same sectorvia Felix Baker and Julian Baker
-
Incyte Corp. Same sectorvia Felix Baker and Julian Baker
-
Kymera Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Neurogene Inc. Same sectorvia Felix Baker and Julian Baker
-
Prelude Therapeutics Incorporated Same sectorvia Felix Baker and Julian Baker
-
Replimune Group Inc. Same sectorvia Felix Baker and Julian Baker
-
TScan Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
vTv Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
- via Kimberly J. Popovits
-
Castle Biosciences Inc. Same sectorvia G. Bradley Cole
-
Connect Biopharma Holdings Limited Same sectorvia Barry D. Quart
-
Heron Therapeutics Inc. Same sectorvia Barry D. Quart
-
Kardigan Inc. Same sectorvia Kimberly J. Popovits
-
Kura Oncology Inc. Same sectorvia Thomas Malley
-
Protara Therapeutics Inc. Same sectorvia Richard S. Levy
-
Rhythm Pharmaceuticals Inc. Same sectorvia Kimberly J. Popovits
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $121,874,556
- 89 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +145,763 | $17.92 | $2,612,073 |
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −1,460 | $92.35 | $134,831 |
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −11,335 | $93.54 | $1,060,276 |
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −81,742 | $94.20 | $7,700,096 |
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −29,845 | $95.48 | $2,849,601 |
| Nov 4, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −26,918 | $96.05 | $2,585,474 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +89,089 | $8.83 | $786,656 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Option exercise | +41,237 | $17.92 | $738,967 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −1,214 | $90.77 | $110,195 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −68,664 | $92.70 | $6,365,153 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −145,708 | $93.53 | $13,628,069 |
| Nov 3, 2026 | Sanj K. Patel Director, Officer (CHAIRMAN & CEO) | Open-market sale | −4,584 | $94.25 | $432,042 |
| Nov 2, 2026 | Ragosa Mark Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +9,636 | $10.76 | $103,683 |
| Nov 2, 2026 | Ragosa Mark Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +5,388 | $11.10 | $59,807 |
| Nov 2, 2026 | Ragosa Mark Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +12,123 | $11.97 | $145,112 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Kiniksa Pharmaceuticals International plc
Who is the CEO of Kiniksa Pharmaceuticals International plc?
Sanj K. Patel is Kiniksa Pharmaceuticals International plc's CHAIRMAN & CEO.
How many directors are on Kiniksa Pharmaceuticals International plc's board?
Kiniksa Pharmaceuticals International plc's board has 10 directors: Barry D. Quart, Felix Baker, G. Bradley Cole, Julian Baker, Kimberly J. Popovits, Meta Cantey Boyd, Richard S. Levy, Sanj K. Patel, Thomas Malley and Tracey L. McCain.
Are Kiniksa Pharmaceuticals International plc insiders buying or selling shares?
Over the last 12 months, Kiniksa Pharmaceuticals International plc insiders made no open-market purchases and sold $121.9 million of shares in 89 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="kiniksa-pharmaceuticals-international-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.